SLFN11 promoter methylation leads to decreased expression, which is significantly associated with shortened progression-free survival (PFS) and overall survival (OS) in patients with serous ovarian cancer (6), further confirming the key role of SLFN11 expression level in prognosis. This evidence concerns the gene SLFN11 and ovarian serous adenocarcinoma.